The Johnson & Johnson’s coronavirus one-dose vaccine is considered safe and it also seems to spawn a promising immune reaction in both the elderly and the youthful volunteers, as documented in a publication of the New England Journal of Medicine.
Johnson & Johnson’s researchers haphazardly allocated healthy adults ranging in ages between eighteen years old and fifty-five years old and then those that are sixty-five years old and older to be injected with either a low or high dosage of the vaccine, created by them, preferred to as Ad26.COV2.S or a placebo. There were some individuals that participated within the eighteen to fifty-five age group selected to be injected a second time.
Many of the participants created noticeable neutralizing antibodies, which the scientists believe would play a vital part in fighting against the virus and defending the cells after twenty-eight days have passed, as stated by the data from the trials. Once the trial reached day fifty-seven, every single participant produced detectable antibodies, in spite of the age category or dosage of the vaccine, they also continued to be stable for at least seventy-one days within the eighteen to fifty-five age grouping.
The most typical side effects experienced were pain at the injection site, muscle aches, headaches, fatigue, and fever, as documented in the data for trials. Less common side effects were seen in the older age group, possibly due to the fact that they only received one vaccination dosage. Those who received the lower dosage of the vaccination also displayed reduced signs of side effects.
According to Dr. Paul Stoffels, the chief scientific officer at Johnson & Johnson indicated that phase one and two clinical data from the trials displays a single injection of the vaccine produces sustainable antibodies. He then added that it gives confidence that the vaccination will be extremely effective in the fight against the coronavirus.
During the clinical trials, eight hundred and five individuals volunteered, the results of which were released in January 2021. Johnson & Johnson is said to be utilizing the same technology to develop this vaccine for the coronavirus as it used for the Ebola vaccine.
United States officials were eagerly awaiting the authorization of the Johnson & Johnson vaccine, stating that it would require an assortment of vaccines and drugs in order to defeat the coronavirus, which from the beginning of the pandemic has taken the lives of more than half a million Americans.
Once the Johnson & Johnson vaccine was approved at the end of February 2021, it became the third vaccine to be cleared by the Food and Drug Administration to be administered within the United States, following the approval of Pfizer-BioNtech vaccine on December 11, 2020, and Moderna vaccine on December 18, 2020, one week later.
The data from the trials were released after complaints from officials that the speed of vaccinations was very slow, as the demand far exceeds the supply. The Centers for Disease Control and Prevention extended the eligibility for the COVID-19 vaccine guidelines so that it includes those individuals over the age of sixty-five along with persons who have underlying conditions. The state and federal governments are also altering the method in which the COVID-19 vaccines are allocated depending on how fast the states are able to administer the injections and the population size of their elderly.
Nothing like the Moderna and Pfizer approved vaccines, which require the individual to receive two doses of the vaccines about four weeks apart, the vaccine from Johnson and Johnson only requires one injection. This means that individuals will not be required to return to receive another dose, which will ultimately simplify the logistics for the health care providers.
The Department of Health and Human Services disclosed back in August 2020 that it chartered a deal with Janssen, the pharmaceutical subsidiary for Johnson & Johnson, estimated at roughly US one billion dollars for one hundred million doses of the vaccine. This deal provides the federal government with the option of ordering an extra two hundred million doses, as stated by the department.
Johnson & Johnson ships the vaccine at a temperature ranging between two to eight degrees Celsius which is approximately thirty-six to forty-six degrees Fahrenheit. According to officials, at this temperature, it gives the vaccine roughly three months of shelf life, which should be increased as the year develops as more data in stability becomes available. According to Johnson & Johnson, with their other vaccines, it is believed that it could reach as much as a year, however at the start they do not have the data to support this as yet.